Obesity
Obesity is a chronic metabolic condition associated with excess adiposity and significant health risks. Genetic and hormonal factors can shape disease expression.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Obesity in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| POMC, PCSK1 and LEPR |
|
Defined at the solid tumor level and applicable to Obesity and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Obesity. Select a therapy to view the specific approval and eligible tests.
POMC, PCSK1 and LEPR (Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance)